PACMAN-AMI: Vascular Effects of Alirocumab in Acute MI-Patients
Study Details
Study Description
Brief Summary
Coronary artery disease (CAD) is the most frequent cause of mortality in the industrialized world. Hypercholesterolemia is a major risk factor for the development and progression of CAD. While statins currently represent the first-line, gold-standard therapy for primary and secondary prevention of cardiovascular morbidity and mortality, nearly 50% of patients in Europe and Canada treated with statins do not achieve their target levels of low-density lipoprotein cholesterol (LDL-C) or cannot tolerate effective statin doses.
Recently, a growing number of studies of PCSK9 inhibitors in a wide spectrum of patients with hyperlipidemia on or off lipid-lowering therapy, familial hypercholesterolemia, and statin intolerance demonstrated consistent, profound, and sustained reductions in LDL-C with greater magnitude of reduction as compared with high-dose statin regimens. However, the effects of PCSK9 inhibition on coronary plaque morphology remain unknown.
This study will investigate the effect of the PCSK9 inhibitor alirocumab in patients with acute myocardial infarction undergoing percutaneous coronary intervention (PCI) in the infarct-related artery and receiving guideline-recommended high-intensity statin therapy. A serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study will be performed to determine the change in plaque volume at week 52. A total of 294 patients will be enrolled in the study and randomized in a 1:1 ratio to either alirocumab or placebo.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 3 |
Detailed Description
Substudies
-
Biobank/drug monitoring, all sites
-
Lipidomics (n=294), all sites
-
Platelet Function (n=~150), Bern
-
Endothelial Function (n=~150), Bern
-
Neatherosclerosis (n=~294), all sites
-
Neutrophilic Extracellular Trap (NET), (n=~50), Vienna
-
OCT-NIRS/IVUS Matching Substudy (n=~104), Bern
-
Positron Emission Computed Tomography (PET-CT), (n=~50), Copenhagen
-
Shear Stress (n=~294), London
-
Quantitative Flow Ratio (QFR) (n=~294), Bern
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Alirocumab Alirocumab 150 mg/mL, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50. |
Drug: Alirocumab
Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
|
| Placebo Comparator: Placebo Placebo, pre-filled auto-injector pen, every second week, starting at day 1 and up to week 50. |
Drug: Alirocumab
Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
|
Outcome Measures
Primary Outcome Measures
- Change in percent atheroma volume (PAV) [Baseline to week 52]
Change in PAV by greyscale intravascular ultrasound (IVUS)
Secondary Outcome Measures
- Change in total lipid-core burden index (LCBItotal) [Baseline to week 52]
Change in LCBItotal as determined by near infrared spectroscopy (NIRS)
- Change in maximum LCBI in any 4-mm segment (Powered) [Baseline to week 52]
Change in maximum LCBI in any 4-mm segment (maxLCBI4mm) as determined by NIRS
- Change in minimal fibrous cap thickness (Powered) [Baseline to week 52]
Change in minimal fibrous cap thickness as determined by optical coherence tomography (OCT)
- Change in mean fibrous cap thickness [Baseline to week 52]
Change in mean fibrous cap thickness as determined by OCT
- Change in average angular extension (AAE) of macrophages [Baseline to week 52]
Change in AAE of macrophages as determined by OCT
- Change in normalized total atheroma volume (NTAV) [Baseline to week 52]
Change in NTAV by IVUS
- Change in LDL-cholesterol [Baseline to week 52]
Change in LDL-cholesterol
- Change in hsCRP [Baseline to week 52]
Change in hsCRP
- Change in high sensitivity troponin T (hsTnT) [Baseline to week 52]
Change in hsTnT
- Change in N-terminal prohormone of brain natriuretic peptide (NT-pro-BNP) [Baseline to week 52]
Change in NT-pro-BNP
- Change in further biomarkers [Baseline to week 52]
Change in lipid and inflammatory markers and their association with indices of plaque progression/regression
- Death [Baseline to week 52]
Any death, cardiac death
- Non-fatal myocardial infarction [Baseline to week 52]
Any non-fatal myocardial infarction
- Ischemia-driven coronary revascularization [Baseline to week 52]
Any ischemia-driven coronary revascularization
- Stroke [Baseline to week 52]
Any ischemic stroke/transient ischemic attack
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or female, age ≥18 years at screening;
-
Acute myocardial infarction: acute ST-segment elevation myocardial infarction (STEMI) with pain onset within ≤24h, or non-ST segment elevation myocardial infarction (NSTEMI), with at least one coronary segment (culprit lesion) requiring PCI;
-
LDL-C ≥70 mg/dL (≥1.8 mmol/L) assessed prior to, or during PCI in patients who have been receiving any stable statin regimen within ≥ 4 weeks prior to enrollment; OR LDL-C ≥125 mg/dL (≥3.2 mmol/L) in patients who are statin-naïve or have not been on stable statin regimen for ≥ 4 weeks prior to enrollment;
-
At least two major native coronary arteries ("target vessels") each meeting the following criteria for intracoronary imaging immediately following the qualifying PCI procedure: Angiographic evidence of <50% reduction in lumen diameter by angiographic visual estimation;
-
Target vessel deemed to be accessible to imaging catheters and suitable for intracoronary imaging in the proximal (50mm) segment ("target segment");
-
Target vessel may not be a bypass (saphenous vein or arterial) graft or a bypassed native vessel;
-
Target vessel must not have undergone previous PCI within the target segment;
-
Target vessel is not candidate for intervention at the time of qualifying PCI or over the following 6 months in the judgment of the Investigator;
-
Hemodynamic stability allowing the repetitive administration of nitroglycerine;
-
Ability to understand the requirements of the study and to provide informed consent;
-
Willingness to undergo follow-up intracoronary imaging.
Exclusion Criteria:
-
Left-main disease, defined as ≥50% reduction in lumen diameter of the left main coronary artery by angiographic visual estimation;
-
Three-vessel disease, defined as ≥70% reduction in lumen diameter of three major epicardial coronary arteries by angiographic visual estimation or in major branches of one or more of these arteries, irrespective of the localization (proximal 50mm or more distal localization) of the obstructive lesions;
-
History of coronary artery bypass surgery;
-
"Thrombolysis In Myocardial Infarction" (TIMI) flow <2 of the infarct-related artery after PCI;
-
Unstable clinical status (hemodynamic or electrical instability);
-
Significant coronary calcification or tortuosity deemed to preclude IVUS, NIRS and OCT evaluation;
-
Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening;
-
Severe renal dysfunction, defined by estimated glomerular filtration rate <30 ml/min/1.73m2;
-
Active liver disease or hepatic dysfunction;
-
Known intolerance to rosuvastatin OR known statin intolerance;
-
Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel;
-
Known sensitivity to any substances to be administered, including known statin intolerance;
-
Patients who previously received alirocumab or other PCSK9 inhibitor;
-
Patient who received cholesterol ester transfer protein inhibitors in the past 12 months prior to screening;
-
Treatment with systemic steroids or systemic cyclosporine in the past 3 months;
-
Known active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator;
-
Planned surgery within 12 months;
-
Patients who will not be available for study-required visits in the judgment of the Investigator;
-
Current enrollment in another investigational device or drug study;
-
History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer;
-
Estimated life expectancy less than 1 year;
-
Female of childbearing potential (age <50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospital Vienna (AKH) | Wien | Austria | 1090 | |
| 2 | Rigshospitalet | Copenhagen | Denmark | 2100 | |
| 3 | Radboud Univerity, Nijmegen Medical Centre | Nijmegen | Gelderland | Netherlands | 6525 |
| 4 | Erasmus Thoraxcentre | Rotterdam | Netherlands | 3015 | |
| 5 | Basel University Hospital | Basel | Switzerland | 4031 | |
| 6 | Bern University Hospital Inselspital | Bern | Switzerland | 3010 | |
| 7 | Hopitaux Universitaires Geneve | Geneva | Switzerland | 1211 | |
| 8 | Stadtspital Triemli | Zurich | Switzerland | 8063 | |
| 9 | University Hospital Zurich USZ | Zürich | Switzerland | 8091 |
Sponsors and Collaborators
- University Hospital Inselspital, Berne
- Regeneron Pharmaceuticals
Investigators
- Principal Investigator: Lorenz Raeber, Prof., MD, Bern Universitiy Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
- Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951.
- Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Honda S, Shishikura D, Scherer DJ, Borgman M, Brennan DM, Wolski K, Nissen SE. Effect of Evolocumab on Coronary Plaque Composition. J Am Coll Cardiol. 2018 Oct 23;72(17):2012-2021. doi: 10.1016/j.jacc.2018.06.078.
- 2016-01382